9. (Amended) [An] The adenovirus according to claim 1, wherein the heterologous DNA sequence comprises a gene which encodes a product effective to inhibit cell division.

10. (Amended) [An] The adenovirus according to claim 9, wherein the gene is selected from the group consisting of tumour suppressor genes, antisense sequences and ribozymes.

A2 cont

11. (Amended) [An] The adenovirus according to claim 6, wherein the heterologous DNA sequence comprises a gene whose expression product induces apoptosis of a cell infected by said adenovirus.

12. (Amended) A composition comprising [a] the replication defective recombinant adenovirus according to claim 1 and an acceptable carrier.

13. (Amended) [A] The composition according to claim 12, in injectable form.

14. (Amended) The adenovirus of claim [4] 3, wherein the viral promoter is the terminal protein 1 (TP1) gene promoter.

Please add the following new claims:

A3

17. (NEW) The adenovirus according to claim 2, wherein the sequence which is activated by EBNA 1 antigen is the EBNA1 responsive element (EBNA1-RE).

18. (NEW) The adenovirus according to claim 14, wherein the sequence which is activated by EBNA 1 antigen is the EBNA1 responsive element (EBNA1-RE).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

19. (NEW) The adenovirus according to claim 17, wherein said adenovirus is a type Ad5 human adenovirus or a type CAV-2 canine adenovirus.

20. (NEW) The adenovirus of claim 1, wherein the expression signal comprises a promoter sequence from an Epstein-Barr virus or from a human papilloma virus.

21. (NEW) The adenovirus according to claim 20, wherein said adenovirus is a type Ad5 human adenovirus or a type CAV-2 canine adenovirus.

22. (NEW) The adenovirus according to claim 20, wherein the promoter sequence is from an Epstein-Barr virus.

A3 cont

23. (NEW) The adenovirus according to claim 22, wherein the promoter sequence is inducible by EBNA1.

24. (NEW) The adenovirus according to claim 1, wherein the papilloma virus antigen is E6.

25. (NEW) The adenovirus according to claim 2, wherein the expression signal comprises a BCR2 viral promoter.

REMARKS

Applicants respectfully request reconsideration of this application in view of the following remarks.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com